The Food and Drug Administration (FDA) announced new black box warnings for potentially fatal reactivation of hepatitis B viruses (HBV) were added to two drugs – one an immune suppressant and the other an anti-cancer medication. The warnings will be added to the labels of Arzerra (ofatumumab) and Rituxan (rituximab). Arzerra is used to treat chronic lymphocytic leukemia (CLL) in patients who have further disease after treatment with the anti-cancer drugs fludarabine and alemtuzumab. Rituxan is used to treat non-Hodgkin’s lymphoma and CLL. It is also used to treat other medical conditions, including rheumatoid arthritis, granulomatosis with polyanglitis, and microscopic ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.